Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors
(2009) In Neuro-Oncology 11(5). p.514-528- Abstract
- The purpose of this study was to identify new prognostic biomarkers with clinical impact in malignant peripheral nerve sheath tumor (MPNST), a highly aggressive malignancy for which no consensus therapy exists besides surgery. We have used tissue microarrays (TMAs) to assess in situ expression of 14 cell-cycle-regulating proteins in 64 well-characterized MPNST patients: 36 sporadic and 28 with neurofibromatosis type 1 (NF1). We developed a new software application for evaluation and logistics of the TMA images and performed a literature survey of cell cycle proteins in MPNST. For NF1-associated patients, there was a clear association between nuclear expression of p53 and poor survival (p = 0.004). Among the other proteins analyzed, we also... (More)
- The purpose of this study was to identify new prognostic biomarkers with clinical impact in malignant peripheral nerve sheath tumor (MPNST), a highly aggressive malignancy for which no consensus therapy exists besides surgery. We have used tissue microarrays (TMAs) to assess in situ expression of 14 cell-cycle-regulating proteins in 64 well-characterized MPNST patients: 36 sporadic and 28 with neurofibromatosis type 1 (NF1). We developed a new software application for evaluation and logistics of the TMA images and performed a literature survey of cell cycle proteins in MPNST. For NF1-associated patients, there was a clear association between nuclear expression of p53 and poor survival (p = 0.004). Among the other proteins analyzed, we also found significant associations between survival and clinical variables, but none were as strong as that for p53. For the total series of MPNSTs, p53 was shown to be an independent predictor of survival, and patients without remission, with tumor size larger than 8 cm, and with positive p53 expression had a 60 times greater risk of dying within the first 5 years compared with the remaining patients (p = 0.000002). This is the most comprehensive study of in situ protein expression in MPNST so far, and expressed p53 was found to be a strong surrogate marker for outcome. Patients in complete remission with a primary p53-positive MPNST diagnosis may be considered in a high-risk subgroup and candidates for adjuvant treatment. Neuro-Oncology 11, 514-528, 2009 (Posted to Neuro-Oncology [serial online], Doc. D08-00271, January 30, 2009.) (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1517630
- author
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- neurofibroma, cyclin D1, MPNST, NF1, p53
- in
- Neuro-Oncology
- volume
- 11
- issue
- 5
- pages
- 514 - 528
- publisher
- Oxford University Press
- external identifiers
-
- wos:000270494800006
- scopus:70349628640
- ISSN
- 1523-5866
- DOI
- 10.1215/15228517-2008-127
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Clinical Genetics (013022003), Pathology, (Lund) (013030000)
- id
- 6d4b684b-b987-4b7c-91fa-a464fc9a2bc3 (old id 1517630)
- date added to LUP
- 2016-04-01 11:45:33
- date last changed
- 2022-04-05 04:39:09
@article{6d4b684b-b987-4b7c-91fa-a464fc9a2bc3,
abstract = {{The purpose of this study was to identify new prognostic biomarkers with clinical impact in malignant peripheral nerve sheath tumor (MPNST), a highly aggressive malignancy for which no consensus therapy exists besides surgery. We have used tissue microarrays (TMAs) to assess in situ expression of 14 cell-cycle-regulating proteins in 64 well-characterized MPNST patients: 36 sporadic and 28 with neurofibromatosis type 1 (NF1). We developed a new software application for evaluation and logistics of the TMA images and performed a literature survey of cell cycle proteins in MPNST. For NF1-associated patients, there was a clear association between nuclear expression of p53 and poor survival (p = 0.004). Among the other proteins analyzed, we also found significant associations between survival and clinical variables, but none were as strong as that for p53. For the total series of MPNSTs, p53 was shown to be an independent predictor of survival, and patients without remission, with tumor size larger than 8 cm, and with positive p53 expression had a 60 times greater risk of dying within the first 5 years compared with the remaining patients (p = 0.000002). This is the most comprehensive study of in situ protein expression in MPNST so far, and expressed p53 was found to be a strong surrogate marker for outcome. Patients in complete remission with a primary p53-positive MPNST diagnosis may be considered in a high-risk subgroup and candidates for adjuvant treatment. Neuro-Oncology 11, 514-528, 2009 (Posted to Neuro-Oncology [serial online], Doc. D08-00271, January 30, 2009.)}},
author = {{Brekke, Helge R. and Kolberg, Matthias and Skotheim, Rolf I. and Hall, Kirsten S. and Bjerkehagen, Bodil and Risberg, Bjorn and Domanski, Henryk and Mandahl, Nils and Liestol, Knut and Smeland, Sigbjorn and Danielsen, Havard E. and Mertens, Fredrik and Lothe, Ragnhild A.}},
issn = {{1523-5866}},
keywords = {{neurofibroma; cyclin D1; MPNST; NF1; p53}},
language = {{eng}},
number = {{5}},
pages = {{514--528}},
publisher = {{Oxford University Press}},
series = {{Neuro-Oncology}},
title = {{Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors}},
url = {{http://dx.doi.org/10.1215/15228517-2008-127}},
doi = {{10.1215/15228517-2008-127}},
volume = {{11}},
year = {{2009}},
}